Interactions between intracerebral human immunodeficiency virus-1 glycoprotein 120 and systemic heroin on expression of messenger ribonucleic acid (mrna) of inducible nitric oxide synthase, interleukin-1β, tumor necrosis factor-α, and cyclooxygenase-2 in hippocampus and cortex brain tissue of the lewis rat... Glycoprotein 120 (gp120), a coat protein of HIV, has been implicated as a possible causative factor...
Major article hiv-1 virologic and immunologic progression and initiation of antiretroviral therapy among hiv-1–infected subjects in a trial of the efficacy of recombinant glycoprotein... This multicenter, randomized, placebo-controlled trial of a recombinant glycoprotein 120 vaccine included 5403 initially HIV-negative volunteers who were monitored for 3 years...
Major article correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of hiv-1 infection in a phase 3... An objective of the first efficacy trial of a candidate vaccine containing recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein 120 (rgp120) antigens was to assess correlations between antibody responses to rgp120 and the incidence of HIV-1 infection...
Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120.An enzyme-linked immunosorbent assay (ELISA) that can measure picogram quantities of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein 120 (gp120) in cell culture medium or body fluids has been developed...
